References
- Charles NJ, Boyer DF. Mixed-phenotype acute leukemia: diagnostic criteria and pitfalls. Arch Pathol Lab Med. 2017;141(11):1462–1468.
- Yan L, Ping N, Zhu M, et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica. 2012;97(11):1708–1712.
- Maruffi M, Sposto R, Oberley MJ, et al. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia. 2018;32(7):1515–1528.
- Shi R, Munker R. Survival of patients with mixed phenotype acute leukemias: a large population-based study. Leuk Res. 2015;39(6):606–616.
- Takahashi K, Wang F, Morita K, et al. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018;9(1):2670
- Xiao W, Bharadwaj M, Levine M, et al. PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood Adv. 2018;2(23):3526–3539.
- Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373–379.
- Antar AI, Otrock ZK, Jabbour E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34(3):682–696.
- Munker R, Labopin M, Esteve J, et al. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102(12):2134–2140.
- Claire Andrews TM, Arruda A, Chan S, et al. Patients with relapsed mixed phenotype acute leukemia have short remission duration with re-induction: a single center experience EHA library. 2019;2019(1).
- Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–850.
- Shimizu H, Yokohama A, Hatsumi N, et al. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol. 2014;93(4):297–301.
- Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
- Burchert A, Bug G, Finke J, et al. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial. Blood. 2018;132(Supplement 1):661–661.
- Estey E, Karp JE, Emadi A, et al. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?. Leukemia. 2020;34(3):671–681.
- Gnanapandithan K. Atraumatic splenic rupture in acute myeloid leukemia. Cleve Clin J Med. 2019;86(11):715–716.
- Aydin AA, Şenocak R, Bilge S, et al. Nontraumatic splenic rupture as the initial manifestation of acute myeloid leukemia in emergency department. Am J Emerg Med. 2016;34(8):1731.e1–1731.e3.
- Kuba A, Szotkowski T, Rohon P, et al. Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):294–298.
- Gascho D, Huber B, Bolliger SA, et al. Splenic rupture and mediastinal mass associated with rare TdT-negative T-LBL/T-ALL lead to sudden death of a juvenile. Forensic Sci Med Pathol. 2016;12(4):523–526.
- Renzulli P, Hostettler A, Schoepfer AM, et al. Systematic review of atraumatic splenic rupture. Br J Surg. 2009;96(10):1114–1121.
- Bernat S, Garcia Boyero R, Guinot M, et al. Pathologic rupture of the spleen as the initial manifestation in acute lymphoblastic leukemia. Haematologica. 1998;83(8):760–761.
- Aiolfi A, Inaba K, Strumwasser A, et al. Splenic artery embolization versus splenectomy: Analysis for early in-hospital infectious complications and outcomes. J Trauma Acute Care Surg. 2017;83(3):356–360.